Measure: CMS136
Follow-Up Care for Children Prescribed ADHD Medication (ADD)
Measure Versions
eMeasure Code |
Measure Year |
Full Version Number |
Title |
CMS136v13 |
2024 |
13.0.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v12 |
2023 |
12 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v11 |
2022 |
11.1.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v10 |
2021 |
10.2.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v9 |
2020 |
9.1.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v8 |
2019 |
8.3.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v7 |
2018 |
7.1.000 |
Follow-Up Care for Children Prescribed ADHD Medication (ADD) |
CMS136v6 |
2017 |
6.0.000 |
ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication |
Description
Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.
a. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.
b. Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.
Guidance
Patient Group Definitions
Group |
Description |
Instructions Links |
Initial Population | Initial Population 1: Children 6-12 years of age as of the Intake Period who were prescribed an ADHD medication during the Intake Period and who had a visit during the measurement period. Children are removed if they were actively on ADHD medication in the 120 days prior to the IPSD, or had an acute inpatient stay with a principal diagnosis of mental, behavioral or neurodevelopmental disorder during the Initiation Phase.
Initial Population 2: Children 6-12 years of age as of the Intake Period who were prescribed an ADHD medication during the Intake Period and remained on the medication for at least 210 days during the 301-day period, beginning on the IPSD through 300 days after the IPSD, and who had a visit during the measurement period. Children are removed if they were actively on ADHD medication in the 120 days prior to the IPSD, or had an acute inpatient stay with a principal diagnosis of mental, behavioral or neurodevelopmental disorder during the Continuation and Maintenance Phase. | Webchart Instructions |
Denominator | Equals Initial Population | Webchart Instructions |
Denominator Exclusions | Exclude patients diagnosed with narcolepsy at any point in their history or during the measurement period.
Exclude patients who are in hospice care for any part of the measurement period. | Webchart Instructions |
Numerator | Numerator 1: Patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase.
Numerator 2: Patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase, and at least two follow-up visits during the 31-300 days after the IPSD. | Webchart Instructions |
Numerator Exclusions | Not Applicable | Webchart Instructions |
Denominator Exceptions | None | |
Details
Full eMeasure Code |
eMeasure Identifier |
Measure Year |
Version |
NQF # |
GUID |
CMS136v12 |
136 |
2023 |
12 |
N/A |
703cc49b-b653-4885-80e8-245a057f5ae9 |
Steward |
Developer |
Endorsed By |
National Committee for Quality Assurance |
National Committee for Quality Assurance |
None |
Scoring Method |
Measure Type |
Stratification |
Risk Adjustment |
Proportion |
Process |
None |
None |
Rate Aggregation
None
Improvement Notation
Higher score indicates better quality
Rationale
Clinical Recommendation Statement
Definition
Transmission Format
Applicable Value Sets
Category |
Value Set |
OID |
Diagnosis |
Narcolepsy |
2.16.840.1.113883.3.464.1003.114.12.1011 |
Encounter, Performed |
Behavioral Health Follow-up Visit |
2.16.840.1.113883.3.464.1003.101.12.1054 |
Encounter, Performed |
Encounter Inpatient |
2.16.840.1.113883.3.666.5.307 |
Encounter, Performed |
Home Healthcare Services |
2.16.840.1.113883.3.464.1003.101.12.1016 |
Encounter, Performed |
Hospice Encounter |
2.16.840.1.113883.3.464.1003.1003 |
Encounter, Performed |
Hospital Observation Care - Initial |
2.16.840.1.113883.3.464.1003.101.12.1002 |
Encounter, Performed |
Office Visit |
2.16.840.1.113883.3.464.1003.101.12.1001 |
Encounter, Performed |
Online Assessments |
2.16.840.1.113883.3.464.1003.101.12.1089 |
Encounter, Performed |
Outpatient Consultation |
2.16.840.1.113883.3.464.1003.101.12.1008 |
Encounter, Performed |
Preventive Care - Established Office Visit, 0 to 17 |
2.16.840.1.113883.3.464.1003.101.12.1024 |
Encounter, Performed |
Preventive Care Services - Group Counseling |
2.16.840.1.113883.3.464.1003.101.12.1027 |
Encounter, Performed |
Preventive Care Services-Individual Counseling |
2.16.840.1.113883.3.464.1003.101.12.1026 |
Encounter, Performed |
Preventive Care- Initial Office Visit, 0 to 17 |
2.16.840.1.113883.3.464.1003.101.12.1022 |
Encounter, Performed |
Psych Visit - Diagnostic Evaluation |
2.16.840.1.113883.3.526.3.1492 |
Encounter, Performed |
Psych Visit - Psychotherapy |
2.16.840.1.113883.3.526.3.1496 |
Encounter, Performed |
Psychotherapy and Pharmacologic Management |
2.16.840.1.113883.3.464.1003.101.12.1055 |
Encounter, Performed |
Telephone Visits |
2.16.840.1.113883.3.464.1003.101.12.1080 |
Intervention, Order |
Hospice Care Ambulatory |
2.16.840.1.113883.3.526.3.1584 |
Intervention, Performed |
Hospice Care Ambulatory |
2.16.840.1.113883.3.526.3.1584 |
Medication, Active |
ADHD Medications |
2.16.840.1.113883.3.464.1003.196.12.1171 |
Medication, Order |
ADHD Medications |
2.16.840.1.113883.3.464.1003.196.12.1171 |
Patient Characteristic Ethnicity |
Ethnicity |
2.16.840.1.114222.4.11.837 |
Patient Characteristic Payer |
Payer |
2.16.840.1.114222.4.11.3591 |
Patient Characteristic Race |
Race |
2.16.840.1.114222.4.11.836 |
Patient Characteristic Sex |
ONC Administrative Sex |
2.16.840.1.113762.1.4.1 |
References
Disclaimer
Copyright
Source:
https://ecqi.healthit.gov/ecqm/measures/cms136v1